Navigation Links
Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
Date:1/22/2008

identifying and licensing clinically enabled compounds like rufinamide allows Synosia to quickly move into smart, efficient clinical trials designed to rapidly establish proof of concept in new therapeutic areas," said Synosia Chief Executive Officer and President Ian Massey. "Rufinamide, a structurally novel compound with proven efficacy in epilepsy and with an extensive safety database, was a perfect candidate to demonstrate the soundness of our strategy. The impressive speed in which this trial was designed, executed and completed is a real highlight for us."

About Rufinamide

The drug was originally discovered and developed by Novartis, which granted certain licensing rights to Eisai of Japan in 2004. In January 2007, Eisai received marketing authorisation in the European Union for Inovelon(R) (rufinamide) as adjunctive anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. Eisai has also submitted an NDA for rufinamide to the US Food and Drug Administration (FDA) for adjunctive therapy in adults and adolescents. The extensive clinical development program for rufinamide in epilepsy has generated over 2500 patient-years of exposure to the drug.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialise innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta, including two marketed drugs that will be tested in new indications, extending their reach into new therapeutic areas with combined sales potential in excess of US$2.5 billion. Synosia has offices in Basel, Switzerland, and South San Francisco, CA.

Synosia Therapeutics has raised US$32.5 million funding from Versant Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo Park, CA) a
'/>"/>

SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... -- After litigating and negotiating patent infringement claims ... United States patent RE43,651 (the ,651 ... the United States without any admission or concession ... As a result of the parties, settlement, the US District ... dismissed the case without prejudice. Under the ...
(Date:8/26/2015)... ... August 26, 2015 , ... The 2015 Epigenomics & Metabolomics ... cell technology start-up company Asymmetrex to share the first report on progress ... new biomarker for counting adult tissue stem cells. , With a name like “H2A.Z ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets ... in Knapp, Wis. The company has added a AS16 Sharples centrifuge to harvest ... collection during bacterial or fungal fermentation process development. , The new centrifuge ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... and rackmount computing infrastructure, today announced the launch of its next generation, ... latest system boasts two distinct, individually sledded workstation nodes in each 1U ...
Breaking Biology Technology:P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4New centrifuge and fermentor expand product development capacity at Vets Plus 2Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 2Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 3
... S*BIO Pte Ltd today announced that,the U.S. ... drug,designation to SB1518, its potent and orally-active JAK2 ... FDA accepted S*BIO,s,application upon review of preclinical data ... very good,tolerability of the JAK2 inhibitor., "We ...
... 13 Johnson & Johnson today announced that,Professor ... Sir,Ravinder N. Maini, FRCP, FMedSci, FRS of the ... named the recipients of the,2008 Dr. Paul Janssen ... of world-renowned scientists., The award salutes the ...
... May 12 Meditor Pharmaceuticals Ltd.,announced today the appointment ... Advisor to the company., Dr. Schachner has been ... will now take a more active role in the ... Head of the Cardiac Surgery,Department at Wolfson Medical Center ...
Cached Biology Technology:S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders 2Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 2Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 3Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 4Two New Appointments at Meditor Pharmaceuticals Ltd. 2
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... new extinct camel species by University of Florida scientists sheds ... containing more than half the world,s biodiversity and some of ... the Journal of Vertebrate Paleontology , the study is ... part of an international project in Panama. Funded with a ...
... While some scientists report engineering a super virulent strain of ... significant percentage of the human population, another group of researchers ... one day help mitigate the deadly effects of all flu ... of the Journal of Leukocyte Biology , ...
... will soon host its annual Spring Review from 5 ... be held at 950 Glebe Road, Suite 210, in ... assessment of AFOSR,s research portfolio. , Since its ... in extramural basic research programs at leading universities and ...
Cached Biology News:UF scientists name new ancient camels from Panama Canal excavation 2UF scientists name new ancient camels from Panama Canal excavation 3New light shed on cause of lung injury in severe flu 2